Autoimmune enteropathy (AIE) is a rare condition in which the immune system attacks the lining of the small intestine, causing severe, persistent diarrhea and an inability to absorb nutrients from food. It affects fewer than 1 in 100,000 infants and is even rarer in adults. Unlike more common gut conditions, it does not improve with dietary changes, including a gluten-free diet, and typically requires immune-suppressing treatment.
How AIE Affects the Small Intestine
In a healthy small intestine, the inner lining is covered in tiny finger-like projections called villi. These villi dramatically increase the surface area available for absorbing nutrients from food. In autoimmune enteropathy, the immune system produces antibodies that target the cells lining the gut. Two types of antibodies are particularly important: anti-enterocyte antibodies, which attack the absorptive cells themselves, and anti-goblet cell antibodies, which target the mucus-producing cells that protect the intestinal lining.
This immune attack flattens or blunts the villi, a process called villous atrophy. In some cases, goblet cells and other specialized cells in the intestinal lining are significantly reduced or completely absent. Without functioning villi and intact lining cells, the intestine loses its ability to absorb water, fats, vitamins, and other nutrients. The result is watery diarrhea that can persist for weeks or months, along with progressive malnutrition and weight loss.
Symptoms in Infants and Adults
The hallmark symptom is chronic, watery diarrhea lasting more than six weeks that does not respond to any change in diet. In infants, the condition most commonly appears within the first six months of life and can quickly become life-threatening due to dehydration and failure to thrive. Babies may lose weight rapidly and become dependent on intravenous nutrition.
Adults develop the same core symptoms: relentless diarrhea, malabsorption, loss of appetite, and severe weight loss. The average age at diagnosis in adults is around 55. One hospital reported making only 13 adult diagnoses over a 16-year period, and every one of those patients also had another autoimmune disease. Adults with AIE often have coexisting conditions like type 1 diabetes, thyroid disease, or rheumatoid arthritis, which can complicate the clinical picture and delay diagnosis.
The Genetic Connection: IPEX Syndrome
Some cases of autoimmune enteropathy in infants are linked to a genetic condition called IPEX syndrome, which stands for immune dysregulation, polyendocrinopathy, enteropathy, X-linked. It is caused by mutations in the FOXP3 gene, which provides instructions for making a protein essential to regulatory T cells. These are the immune cells responsible for preventing the body from attacking its own tissues.
When FOXP3 is nonfunctional, regulatory T cells fail to develop properly, and the immune system loses its ability to distinguish self from foreign invaders. Because IPEX is inherited in an X-linked pattern, it almost exclusively affects boys. The enteropathy in IPEX is often just one piece of a larger syndrome that includes hormonal disorders and skin problems. Not all cases of AIE involve FOXP3 mutations, however. Many adult cases and some pediatric cases occur without any identifiable genetic cause.
How AIE Is Diagnosed
Diagnosis requires meeting several criteria simultaneously. First, the diarrhea must be chronic (lasting at least six weeks) and accompanied by malabsorption. Second, a biopsy of the small intestine must show villous blunting. Third, other causes of villous atrophy, particularly celiac disease, must be ruled out. Blood tests for gut epithelial cell antibodies can help confirm the diagnosis. In one study, 93% of patients tested positive for anti-enterocyte or anti-goblet cell antibodies.
The biopsy findings themselves can vary. The most common pattern, seen in about half of cases, is villous blunting with inflammation in the tissue beneath the surface and damage to the intestinal crypts (the glands at the base of the villi). Some cases show increased immune cells within the surface lining, while others show a near-complete absence of goblet cells or other specialized cell types. This variability is one reason AIE can be difficult to recognize.
How It Differs From Celiac Disease
Because AIE and celiac disease both cause villous atrophy and malabsorption, they can look similar on biopsy. The critical difference is response to diet. Celiac disease improves on a strict gluten-free diet; AIE does not respond to any dietary modification. Refractory celiac disease, a form that also resists dietary treatment, is distinguished by a high number of immune cells within the surface lining of the intestine (more than 40 per 100 epithelial cells), a finding that is typically minimal or absent in AIE. Other conditions that must be considered include common variable immunodeficiency, small bowel lymphoma, and enteropathy caused by certain blood pressure medications.
Treatment and Nutritional Support
Because the damage is driven by an overactive immune system, treatment centers on immunosuppression. Corticosteroids are typically the first approach, often combined with other immune-suppressing medications. The goal is to quiet the immune attack enough for the intestinal lining to recover and resume absorbing nutrients.
In the meantime, many patients require total parenteral nutrition (TPN), which delivers all necessary calories, vitamins, and minerals directly into the bloodstream through an IV line, bypassing the damaged gut entirely. For infants and severely malnourished adults, TPN can be lifesaving while waiting for immunosuppressive therapy to take effect.
Long-Term Outlook
The prognosis for AIE remains challenging, particularly for adults. In one study tracking adult patients over a median follow-up of about 20 months, the relapse-free survival rate dropped from 62.5% at six months to just 37% at four years. Two patients in that cohort died from multiple organ failure, and one developed lymphoma. Relapses are common even with ongoing immunosuppressive treatment, and many patients cycle through periods of remission and flare.
For infants with IPEX syndrome, outcomes depend heavily on the severity of the FOXP3 mutation and how early treatment begins. Bone marrow transplant is sometimes considered for severe cases, as it can replace the defective immune system entirely. For both children and adults, early diagnosis gives the best chance of preventing irreversible nutritional damage and organ complications.